Home›Companies›Biotech & Pharma›Kaigene

Kaigene, Inc.

Develops antibody medicines for people with autoimmune diseases.

Updated Nov 9, 2026·Latest SEC filing Oct 14, 2026·Suggest an edit

About Kaigene

Kaigene is a private company based in Rockville, Maryland, incorporated in 2021 in Delaware. It has reported $56,308,229 raised in two offerings on Form D since March 2022. Its chief executive is Minjae Shin.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 30, 2026Oct 14, 2026$54,958,229of $73.3M target22$2.4MEquityRule 506(b)Form D ↗
Mar 15, 2022Mar 29, 2022$1,350,000of $5.0M target3$450KDebtRule 506(b)Form D ↗
Total, two offerings$56,308,229

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Kaigene's Form D filed Oct 14, 2026.

MS
Minjae Shin
Chief Executive Officer; President and director
JP
Jihoon Park
Executive officer
KM
Kyunghyun Min
Chief Technology Officer; Senior Vice President and director
TJ
Tae Heum Jeong
Director
Also an executive officer at KSV.

Sources

  1. SECKaigene, Inc. filing history
  2. CompanyKaigene overview and leadership